To validate the CRISPR-ENHANCE technology, we first selected a clinically relevant nucleic acid biomarker, Prostate Cancer Antigen 3 (PCA3/DD3), which is one of the most overexpressed genes in prostate cancer tissue and excreted in patients’ urine. This evidence concerns the gene PCA3 and prostate carcinoma.